GTBL Signs Euro 158M Deal for Sanofi's Ant-TB & Anti-Infective Brands

Gujarat Themis Biosyn Limited (GTBL) has announced a major step in its global expansion with the signing of an agreement to acquire a portfolio of anti-TB & anti-infective brands from Sanofi.

The GTBL acquisition of Sanofi TB portfolio is subject to regulatory approvals, including antitrust and foreign direct investment clearances across multiple regions.

The deal includes 13 established branded generic products currently sold in more than 55 countries across Europe, the Middle East, and Africa.

The portfolio generated net sales of around EUR 62 million in 2025, making it a strong addition to GTBL’s growing international business. As part of the agreement, GTBL will acquire marketing authorizations, brands, regulatory dossiers, inventory, and related commercial rights. However, no manufacturing facilities or employees will be transferred, keeping the transaction asset-light.

Also Read: Consumer Trust in OTC Products: The Science Behind Safety

Valued at EUR 158 million, the acquisition will be funded through a mix of debt and equity and is expected to be earnings accretive. The company sees strong potential in branded generics, improved operating leverage, and deeper vertical integration. The GTBL acquisition of Sanofi TB portfolio also supports its strategy to strengthen its presence in the anti-infective segment and expand into regulated and semi-regulated markets.

GTBL expects forward integration benefits by using its fermentation-based intermediates and API capabilities to support finished dosage formulations, improving overall margins and efficiency.

Dr Sachin Patel, Managing Director, GTBL, said: “This move would serve as a gateway to extend our patient reach, explore and penetrate new regulated territories, establishing a truly global footprint for our specialized offerings.”

“Controlling the process from fermentation to the final product minimizes supply chain risks and ensures long-term profitability improvement. With multiple levers for value creation under our direct control, this acquisition will position GTBL to deliver consistent, long-term shareholder value while reinforcing our leadership in the fermentation space and growing the impact we have in global healthcare.”